MCL1 and myelodysplastic syndrome: Upregulation of MCL-1 was observed in VEN-resistant AML and MDS, and the combination of VEN and MCL-1 inhibitor was synergistic in all MDS subtypes without significant injury to normal hematopoiesis in humanized MISTRG6 mice [6].